{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T20:54:55Z","timestamp":1790456095947,"version":"4.1.0"},"reference-count":297,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013671","name":"Sun Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013671","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020629","name":"Universitatea \u0218tefan cel Mare din Suceava","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020629","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes & Metabolic Syndrome: Clinical Research & Reviews"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.dsx.2025.103209","type":"journal-article","created":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T19:26:46Z","timestamp":1741202806000},"page":"103209","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Consensus guidelines for the diagnosis and management of metabolic dysfunction-associated steatotic liver disease in adult Asian Indians with type 2 diabetes"],"prefix":"10.1016","volume":"19","author":[{"given":"Anoop","family":"Misra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Shafi","family":"Kuchay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9011-8632","authenticated-orcid":false,"given":"Amerta","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seema","family":"Gulati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narendra Singh","family":"Choudhary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deep","family":"Dutta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Praveen","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naval K.","family":"Vikram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashu","family":"Rastogi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akash","family":"Shukla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alpesh","family":"Goyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anand V.","family":"Kulkarni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil","family":"Chandra Anand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil","family":"Arora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anu","family":"Mathew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aravinda","family":"Jagadeesha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arijit","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arvind Kumar","family":"Ojha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atul","family":"Luthra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Awadhesh Kumar","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Banshi","family":"Saboo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bharat","family":"Saboo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brij Mohan","family":"Makkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chitra","family":"Selvan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chundamannil E.","family":"Eapen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debmalya","family":"Sanyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhruvi","family":"Hasnani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinesh","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faraz","family":"Farishta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaurav","family":"Chhaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gourdas","family":"Choudhuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gumpeny R.","family":"Sridhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jothydev","family":"Kesavadev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jugal Kishor","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kannan","family":"Natarajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaushal","family":"Madan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ketan K.","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiran","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunal","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhumita","family":"Premkumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manav","family":"Wadhawan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mangesh","family":"Tiwaskar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayur","family":"Agrawal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nipun","family":"Verma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parikshit","family":"Goswami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parjeet","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piyush","family":"Ranjan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prabhat Kumar","family":"Agrawal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prasanth","family":"Sankar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Purvi","family":"Chawla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh","family":"Agrawal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakhi","family":"Maiwall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rucha","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.V.","family":"Madhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samar","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep","family":"Suri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sangram","family":"Biradar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Kalra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay Kumar","family":"Bhadada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saurav Shishir","family":"Agrawal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Shalimar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seema","family":"Gulati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shashank","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shubhashree Mangesh","family":"Patil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swati","family":"Waghdhare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vipul","family":"Chavda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viswanathan","family":"Mohan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vitull K.","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek A.","family":"Saraswat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yashdeep","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.dsx.2025.103209_bib1","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.clnu.2024.11.016","article-title":"Global burden of disease attributable to metabolic risk factors in adolescents and young adults aged 15-39, 1990-2021","volume":"43","author":"Zhou","year":"2024","journal-title":"Clin Nutr"},{"key":"10.1016\/j.dsx.2025.103209_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2024.155999","article-title":"Global burden of metabolic diseases, 1990-2021","volume":"160","author":"Zhang","year":"2024","journal-title":"Metabolism"},{"issue":"6","key":"10.1016\/j.dsx.2025.103209_bib3","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"78","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.dsx.2025.103209_bib4","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1089\/met.2004.2.14","article-title":"The metabolic syndrome in asian Indians: impact of nutritional and socio-economic transition in India","volume":"2","author":"Wasir","year":"2004","journal-title":"Metab Syndr Relat Disord"},{"issue":"6","key":"10.1016\/j.dsx.2025.103209_bib5","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1089\/met.2009.0024","article-title":"The metabolic syndrome in South Asians: epidemiology, determinants, and prevention","volume":"7","author":"Misra","year":"2009","journal-title":"Metab Syndr Relat Disord"},{"key":"10.1016\/j.dsx.2025.103209_bib6","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1159\/000354952","article-title":"Obesity and the metabolic syndrome in developing countries: focus on South Asians","volume":"78","author":"Misra","year":"2014","journal-title":"Nestle Nutr Inst Workshop Ser"},{"issue":"3","key":"10.1016\/j.dsx.2025.103209_bib7","first-page":"285","article-title":"A case-control study on insulin resistance, metabolic co-variates & prediction score in non-alcoholic fatty liver disease","volume":"129","author":"Bajaj","year":"2009","journal-title":"Indian J Med Res"},{"issue":"48","key":"10.1016\/j.dsx.2025.103209_bib8","doi-asserted-by":"crossref","first-page":"18273","DOI":"10.1073\/pnas.0608537103","article-title":"Increased prevalence of insulin resistance and nonalcoholic fatty liver disease in Asian-Indian men","volume":"103","author":"Petersen","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.dsx.2025.103209_bib9","first-page":"163","article-title":"Consensus statement for diagnosis of obesity, abdominal obesity and the metabolic syndrome for Asian Indians and recommendations for physical activity, medical and surgical management","volume":"57","author":"Misra","year":"2009","journal-title":"J Assoc Phys India"},{"issue":"3 Suppl","key":"10.1016\/j.dsx.2025.103209_bib10","doi-asserted-by":"crossref","first-page":"289S","DOI":"10.1080\/07315724.2010.10719844","article-title":"Obesity, the metabolic syndrome, and type 2 diabetes in developing countries: role of dietary fats and oils","volume":"29","author":"Misra","year":"2010","journal-title":"J Am Coll Nutr"},{"issue":"11\u201312","key":"10.1016\/j.dsx.2025.103209_bib11","article-title":"Rising trends of diabetes in South Asia: a systematic review and meta-analysis","volume":"18","author":"Ranasinghe","year":"2024","journal-title":"Diabetes Metabol Syndr"},{"issue":"10467","key":"10.1016\/j.dsx.2025.103209_bib12","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1016\/S0140-6736(24)02317-1","article-title":"Worldwide trends in diabetes prevalence and treatment from 1990 to 2022: a pooled analysis of 1108 population-representative studies with 141 million participants","volume":"404","author":"Collaboration","year":"2024","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.dsx.2025.103209_bib13","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1007\/s12072-023-10543-8","article-title":"An international multidisciplinary consensus statement on MAFLD and the risk of CVD","volume":"17","author":"Zhou","year":"2023","journal-title":"Hepatol Int"},{"issue":"3","key":"10.1016\/j.dsx.2025.103209_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.dsx.2022.102446","article-title":"Role of diabetologists in the management of nonalcoholic fatty liver disease: primary prevention and screening\/management of fibrosis and cirrhosis","volume":"16","author":"Kuchay","year":"2022","journal-title":"Diabetes Metabol Syndr"},{"issue":"6","key":"10.1016\/j.dsx.2025.103209_bib15","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1016\/j.dsx.2020.11.015","article-title":"Nonalcoholic fatty liver disease should be considered for treatment allocation in standard management algorithms for type 2 diabetes","volume":"14","author":"Kuchay","year":"2020","journal-title":"Diabetes Metabol Syndr"},{"issue":"1","key":"10.1016\/j.dsx.2025.103209_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.jceh.2023.08.007","article-title":"Research on non-alcoholic fatty liver disease from Indian subcontinent: a bibliometric analysis of publications during 2001-2022","volume":"14","author":"Vaishya","year":"2024","journal-title":"J Clin Exp Hepatol"},{"issue":"5","key":"10.1016\/j.dsx.2025.103209_bib17","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.dsx.2025.103209_bib18","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jceh.2022.11.014","article-title":"Indian national association for study of the liver (INASL) guidance paper on nomenclature, diagnosis and treatment of nonalcoholic fatty liver disease (NAFLD)","volume":"13","author":"Duseja","year":"2023","journal-title":"J Clin Exp Hepatol"},{"issue":"7454","key":"10.1016\/j.dsx.2025.103209_bib19","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1136\/bmj.328.7454.1490","article-title":"Grading quality of evidence and strength of recommendations","volume":"328","author":"Atkins","year":"2004","journal-title":"BMJ"},{"issue":"7650","key":"10.1016\/j.dsx.2025.103209_bib20","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.dsx.2025.103209_bib21","doi-asserted-by":"crossref","first-page":"116","DOI":"10.5662\/wjm.v11.i4.116","article-title":"Delphi methodology in healthcare research: how to decide its appropriateness","volume":"11","author":"Nasa","year":"2021","journal-title":"World J Methodol"},{"issue":"7","key":"10.1016\/j.dsx.2025.103209_bib22","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1210\/jcem.87.7.8736","article-title":"Hepatic steatosis, insulin resistance, and adipose tissue disorders","volume":"87","author":"Garg","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"10.1016\/j.dsx.2025.103209_bib23","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S2213-8587(14)70032-4","article-title":"Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome","volume":"2","author":"Yki-Jarvinen","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"10.1016\/j.dsx.2025.103209_bib24","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/hepr.12333","article-title":"Diagnosis and classification of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: current concepts and remaining challenges","volume":"45","author":"Hashimoto","year":"2015","journal-title":"Hepatol Res"},{"issue":"Suppl 1","key":"10.1016\/j.dsx.2025.103209_bib25","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/liv.13299","article-title":"The epidemiology of non-alcoholic fatty liver disease","volume":"37","author":"Bellentani","year":"2017","journal-title":"Liver Int"},{"issue":"11","key":"10.1016\/j.dsx.2025.103209_bib26","doi-asserted-by":"crossref","DOI":"10.3390\/nu12113501","article-title":"Metabolic syndrome: past, present and future","volume":"12","author":"Lemieux","year":"2020","journal-title":"Nutrients"},{"issue":"7","key":"10.1016\/j.dsx.2025.103209_bib27","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.18520\/cs\/v113\/i07\/1303-1310","article-title":"Non-alcoholic fatty liver disease in Asian Indians: relationship with insulin resistance, diabetes and cardiovascular risk","volume":"113","author":"Bhatt","year":"2017","journal-title":"Curr Sci"},{"key":"10.1016\/j.dsx.2025.103209_bib28","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.3389\/fphys.2019.01607","article-title":"Chronic adipose tissue inflammation linking obesity to insulin resistance and type 2 diabetes","volume":"10","author":"Zatterale","year":"2019","journal-title":"Front Physiol"},{"issue":"5","key":"10.1016\/j.dsx.2025.103209_bib29","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1172\/JCI23621","article-title":"Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease","volume":"115","author":"Donnelly","year":"2005","journal-title":"J Clin Investig"},{"issue":"6","key":"10.1016\/j.dsx.2025.103209_bib30","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1016\/j.dsx.2020.09.026","article-title":"Pathophysiological mechanisms underlying MAFLD","volume":"14","author":"Kuchay","year":"2020","journal-title":"Diabetes Metabol Syndr"},{"issue":"2","key":"10.1016\/j.dsx.2025.103209_bib31","doi-asserted-by":"crossref","first-page":"E275","DOI":"10.1152\/ajpendo.00644.2005","article-title":"Saturated fatty acids induce endoplasmic reticulum stress and apoptosis independently of ceramide in liver cells","volume":"291","author":"Wei","year":"2006","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.dsx.2025.103209_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106507","article-title":"Toll-like receptors and metabolic (dysfunction)-associated fatty liver disease","volume":"185","author":"Khanmohammadi","year":"2022","journal-title":"Pharmacol Res"},{"issue":"1","key":"10.1016\/j.dsx.2025.103209_bib33","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41577-019-0198-4","article-title":"The intestinal microbiota fuelling metabolic inflammation","volume":"20","author":"Tilg","year":"2020","journal-title":"Nat Rev Immunol"},{"issue":"5","key":"10.1016\/j.dsx.2025.103209_bib34","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1089\/met.2012.0064","article-title":"Genetic variation in the patatin-like phospholipase domain-containing protein-3 (PNPLA-3) gene in Asian Indians with nonalcoholic fatty liver disease","volume":"11","author":"Bhatt","year":"2013","journal-title":"Metab Syndr Relat Disord"},{"issue":"6","key":"10.1016\/j.dsx.2025.103209_bib35","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1155\/2011\/950102","article-title":"SREBP-2 1784 G\/C genotype is associated with non-alcoholic fatty liver disease in north Indians","volume":"31","author":"Bhatt","year":"2011","journal-title":"Dis Markers"},{"issue":"1","key":"10.1016\/j.dsx.2025.103209_bib36","first-page":"3","article-title":"Body composition and the metabolic syndrome in Asian Indians: a saga of multiple adversities","volume":"16","author":"Misra","year":"2003","journal-title":"Natl Med J India"},{"issue":"4","key":"10.1016\/j.dsx.2025.103209_bib37","first-page":"178","article-title":"Non-obese hyperlipidemic Asian northern Indian males have adverse anthropometric profile","volume":"12","author":"Misra","year":"2002","journal-title":"Nutr Metabol Cardiovasc Dis"},{"issue":"9","key":"10.1016\/j.dsx.2025.103209_bib38","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0024362","article-title":"High prevalence of abdominal, intra-abdominal and subcutaneous adiposity and clustering of risk factors among urban Asian Indians in North India","volume":"6","author":"Bhardwaj","year":"2011","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.dsx.2025.103209_bib39","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/ijo.2010.135","article-title":"Obesity-related non-communicable diseases: south Asians vs white caucasians","volume":"35","author":"Misra","year":"2011","journal-title":"Int J Obes"},{"issue":"2","key":"10.1016\/j.dsx.2025.103209_bib40","first-page":"177","article-title":"Relationship of Xba1 and EcoR1 polymorphisms of apolipoprotein-B gene to dyslipidemia and obesity in Asian Indians in North India","volume":"53","author":"Misra","year":"2001","journal-title":"Indian Heart J"},{"issue":"3","key":"10.1016\/j.dsx.2025.103209_bib41","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/0021-9150(91)90174-2","article-title":"Apolipoprotein B gene polymorphisms are associated with lipid levels in men of South Asian descent","volume":"91","author":"Renges","year":"1991","journal-title":"Atherosclerosis"},{"issue":"4","key":"10.1016\/j.dsx.2025.103209_bib42","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.arcmed.2006.10.013","article-title":"APOC3 promoter polymorphisms C-482T and T-455C are associated with the metabolic syndrome","volume":"38","author":"Miller","year":"2007","journal-title":"Arch Med Res"},{"issue":"3","key":"10.1016\/j.dsx.2025.103209_bib43","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/j.1399-0004.1993.tb03861.x","article-title":"DNA polymorphisms of the apolipoprotein B gene are associated with obesity and serum lipids in healthy Indians in Singapore","volume":"44","author":"Saha","year":"1993","journal-title":"Clin Genet"},{"issue":"3","key":"10.1016\/j.dsx.2025.103209_bib44","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.dsx.2021.04.014","article-title":"Differential expression of insulin receptor substrate-1(IRS-1) in visceral and subcutaneous adipose depots of morbidly obese subjects undergoing bariatric surgery in a tertiary care center in north India; SNP analysis and correlation with metabolic profile","volume":"15","author":"Sharma","year":"2021","journal-title":"Diabetes Metabol Syndr"},{"issue":"4","key":"10.1016\/j.dsx.2025.103209_bib45","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.cgh.2014.04.014","article-title":"Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies","volume":"13","author":"Singh","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.dsx.2025.103209_bib46","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1002\/hep.31014","article-title":"Effect of metabolic traits on the risk of cirrhosis and hepatocellular cancer in nonalcoholic fatty liver disease","volume":"71","author":"Kanwal","year":"2020","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.dsx.2025.103209_bib47","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1177\/1932296816664916","article-title":"Estimation of liver span using MRI for prediction of type 2 diabetes in non-obese asian Indians","volume":"11","author":"Anoop","year":"2017","journal-title":"J Diabetes Sci Technol"},{"issue":"5","key":"10.1016\/j.dsx.2025.103209_bib48","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1111\/1753-0407.12396","article-title":"Diabetes risk prediction model for non-obese Asian Indians residing in North India using cut-off values for pancreatic and intra-abdominal fat volume and liver span","volume":"8","author":"Anoop","year":"2016","journal-title":"J Diabetes"},{"issue":"3","key":"10.1016\/j.dsx.2025.103209_bib49","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.jhep.2013.04.027","article-title":"A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver","volume":"59","author":"Pais","year":"2013","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.dsx.2025.103209_bib50","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.jhep.2004.09.012","article-title":"The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies","volume":"42","author":"Adams","year":"2005","journal-title":"J Hepatol"},{"issue":"12","key":"10.1016\/j.dsx.2025.103209_bib51","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.4158\/EP14044.OR","article-title":"Clinical profile of nonalcoholic Fatty liver disease among young patients with type 1 diabetes mellitus seen at a diabetes speciality center in India","volume":"20","author":"Vendhan","year":"2014","journal-title":"Endocr Pract"},{"issue":"5","key":"10.1016\/j.dsx.2025.103209_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.dsx.2021.102261","article-title":"Retrospective analysis (2009-2017) of factors associated with progression and regression of non-alcoholic fatty liver disease (Hepatic steatosis) in patients with type 2 diabetes seen at a tertiary diabetes centre in Southern India","volume":"15","author":"Kamalraj","year":"2021","journal-title":"Diabetes Metabol Syndr"},{"issue":"3","key":"10.1016\/j.dsx.2025.103209_bib53","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.jceh.2021.11.010","article-title":"Prevalence of non-alcoholic fatty liver disease in India: a systematic review and meta-analysis","volume":"12","author":"Shalimar","year":"2022","journal-title":"J Clin Exp Hepatol"},{"key":"10.1016\/j.dsx.2025.103209_bib54","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.clnesp.2021.08.028","article-title":"High prevalence of hepatic steatosis and hepatic fibrosis in patients with type 2 diabetes mellitus","volume":"46","author":"Gupta","year":"2021","journal-title":"Clin Nutr ESPEN"},{"issue":"8","key":"10.1016\/j.dsx.2025.103209_bib55","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1111\/j.1440-1746.2004.03312.x","article-title":"Non-alcoholic steatohepatitis in type 2 diabetes mellitus","volume":"19","author":"Gupte","year":"2004","journal-title":"J Gastroenterol Hepatol"},{"issue":"7","key":"10.1016\/j.dsx.2025.103209_bib56","first-page":"448","article-title":"Study of prevalence of nonalcoholic fatty liver disease (NAFLD) in type 2 diabetes patients in India (SPRINT)","volume":"61","author":"Kalra","year":"2013","journal-title":"J Assoc Phys India"},{"issue":"4","key":"10.1016\/j.dsx.2025.103209_bib57","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.dsx.2018.01.001","article-title":"Nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus and its association with cardiovascular disease","volume":"12","author":"Vanjiappan","year":"2018","journal-title":"Diabetes Metabol Syndr"},{"issue":"1","key":"10.1016\/j.dsx.2025.103209_bib58","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.diabres.2008.11.039","article-title":"Prevalence of non-alcoholic fatty liver disease in urban south Indians in relation to different grades of glucose intolerance and metabolic syndrome","volume":"84","author":"Mohan","year":"2009","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.dsx.2025.103209_bib59","first-page":"593","article-title":"Clinicopathological profile of hepatic involvement in type-2 diabetes mellitus and its significance","volume":"56","author":"Banerjee","year":"2008","journal-title":"J Assoc Phys India"},{"key":"10.1016\/j.dsx.2025.103209_bib60","first-page":"351","article-title":"Prevalence of non-alcoholic fatty liver disease and its correlation with coronary risk factors in patients with type 2 diabetes","volume":"59","author":"Agarwal","year":"2011","journal-title":"J Assoc Phys India"},{"issue":"3","key":"10.1016\/j.dsx.2025.103209_bib61","doi-asserted-by":"crossref","first-page":"563","DOI":"10.4103\/2249-4863.222018","article-title":"Hepatobiliary dysfunction in Type-2 diabetes mellitus","volume":"6","author":"Manoria","year":"2017","journal-title":"J Family Med Prim Care"},{"issue":"8","key":"10.1016\/j.dsx.2025.103209_bib62","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1002\/jgh3.12606","article-title":"Prevalence of clinically relevant liver fibrosis due to nonalcoholic fatty liver disease in Indian individuals with type 2 diabetes","volume":"5","author":"Kuchay","year":"2021","journal-title":"JGH Open"},{"issue":"3","key":"10.1016\/j.dsx.2025.103209_bib63","doi-asserted-by":"crossref","first-page":"386","DOI":"10.4103\/ijcm.ijcm_1213_21","article-title":"Anthropometric indices and type 2 diabetes mellitus as a risk factor in predicting nonalcoholic fatty liver disease - a prospective study in Indian population","volume":"47","author":"Suvarna","year":"2022","journal-title":"Indian J Community Med"},{"key":"10.1016\/j.dsx.2025.103209_bib64","first-page":"205","article-title":"Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus","volume":"57","author":"Prashanth","year":"2009","journal-title":"J Assoc Phys India"},{"issue":"Supplement_1","key":"10.1016\/j.dsx.2025.103209_bib65","doi-asserted-by":"crossref","first-page":"S59","DOI":"10.2337\/dc25-S004","article-title":"4. Comprehensive medical evaluation and assessment of comorbidities: standards of care in diabetes-2025","volume":"48","year":"2025","journal-title":"Diabetes Care"},{"key":"10.1016\/j.dsx.2025.103209_bib66","doi-asserted-by":"crossref","first-page":"102989","DOI":"10.1016\/j.dsx.2024.102989","article-title":"Revised definition of obesity in Asian Indians living in India","author":"Misra","year":"2025","journal-title":"Diabetes Metab Syndr"},{"key":"10.1016\/j.dsx.2025.103209_bib67","first-page":"163","article-title":"Consensus statement for diagnosis of obesity, abdominal obesity and the metabolic syndrome for Asian Indians and recommendations for physical activity, medical and surgical management","volume":"57","author":"Misra","year":"2009","journal-title":"J Assoc Phys India"},{"key":"10.1016\/j.dsx.2025.103209_bib68","article-title":"Revised definition of obesity in Asian Indians living in India","author":"Misra","year":"2024","journal-title":"Diabetes Metabol Syndr"},{"key":"10.1016\/j.dsx.2025.103209_bib69","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-8587(24)00316-4","article-title":"Definition and diagnostic criteria of clinical obesity","author":"Rubino","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10","key":"10.1016\/j.dsx.2025.103209_bib70","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0140447","article-title":"Body fat patterning, hepatic fat and pancreatic volume of non-obese asian Indians with type 2 diabetes in north India: a case-control study","volume":"10","author":"Misra","year":"2015","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.dsx.2025.103209_bib71","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.3748\/wjg.v21.i5.1650","article-title":"Central obesity and nonalcoholic fatty liver disease risk after adjusting for body mass index","volume":"21","author":"Pang","year":"2015","journal-title":"World J Gastroenterol"},{"issue":"1","key":"10.1016\/j.dsx.2025.103209_bib72","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/sj.ijo.0803111","article-title":"Waist circumference cutoff points and action levels for Asian Indians for identification of abdominal obesity","volume":"30","author":"Misra","year":"2006","journal-title":"Int J Obes"},{"issue":"9","key":"10.1016\/j.dsx.2025.103209_bib73","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.nut.2005.01.007","article-title":"Waist circumference criteria for the diagnosis of abdominal obesity are not applicable uniformly to all populations and ethnic groups","volume":"21","author":"Misra","year":"2005","journal-title":"Nutrition"},{"issue":"4","key":"10.1016\/j.dsx.2025.103209_bib74","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.jceh.2017.05.005","article-title":"Simple anthropometric indices are useful for predicting non-alcoholic fatty liver disease [NAFLD] in asian Indians","volume":"7","author":"Singh","year":"2017","journal-title":"J Clin Exp Hepatol"},{"issue":"10","key":"10.1016\/j.dsx.2025.103209_bib75","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1089\/met.2016.0041","article-title":"Waist-to-Height ratio compared to standard obesity measures as predictor of cardiometabolic risk factors in Asian Indians in north India","volume":"14","author":"Vikram","year":"2016","journal-title":"Metab Syndr Relat Disord"},{"issue":"1","key":"10.1016\/j.dsx.2025.103209_bib76","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1186\/s12876-021-01824-3","article-title":"Waist-to-height ratio and non-alcoholic fatty liver disease in adults","volume":"21","author":"Sheng","year":"2021","journal-title":"BMC Gastroenterol"},{"issue":"3","key":"10.1016\/j.dsx.2025.103209_bib77","doi-asserted-by":"crossref","first-page":"347","DOI":"10.4103\/ijem.IJEM_31_18","article-title":"Neck circumference to height ratio is a reliable predictor of liver stiffness and nonalcoholic fatty liver disease in prediabetes","volume":"22","author":"Mondal","year":"2018","journal-title":"Indian J Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.dsx.2025.103209_bib78","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.ihj.2017.04.015","article-title":"Management of obesity in adult Asian Indians","volume":"69","author":"Behl","year":"2017","journal-title":"Indian Heart J"},{"issue":"2","key":"10.1016\/j.dsx.2025.103209_bib79","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.pcd.2024.01.003","article-title":"Acanthosis nigricans independently predicts hepatic fibrosis in people with type 2 diabetes in North India","volume":"18","author":"Dutta","year":"2024","journal-title":"Prim Care Diabetes"},{"issue":"3","key":"10.1016\/j.dsx.2025.103209_bib80","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/cld.1142","article-title":"Assessment of sarcopenia in chronic liver disease: Indian perspective","volume":"18","author":"Anand","year":"2021","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.dsx.2025.103209_bib81","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2022.101696","article-title":"Non-alcoholic fatty liver disease-related fibrosis and sarcopenia: an altered liver-muscle crosstalk leading to increased mortality risk","volume":"80","author":"Kuchay","year":"2022","journal-title":"Ageing Res Rev"},{"issue":"1","key":"10.1016\/j.dsx.2025.103209_bib82","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s41043-024-00500-y","article-title":"Hand grip strength as a proposed new vital sign of health: a narrative review of evidences","volume":"43","author":"Vaishya","year":"2024","journal-title":"J Health Popul Nutr"},{"issue":"1","key":"10.1016\/j.dsx.2025.103209_bib83","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/HEP.0000000000000845","article-title":"AASLD Practice Guideline on blood-based noninvasive liver disease assessment of hepatic fibrosis and steatosis","volume":"81","author":"Sterling","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.dsx.2025.103209_bib84","doi-asserted-by":"crossref","DOI":"10.1007\/s00330-024-11001-1","article-title":"Evaluation of MRI proton density fat fraction in hepatic steatosis: a systematic review and meta-analysis","author":"Azizi","year":"2024","journal-title":"Eur Radiol"},{"issue":"4","key":"10.1016\/j.dsx.2025.103209_bib85","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.cgh.2022.04.014","article-title":"Mortality outcomes by fibrosis stage in nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"21","author":"Ng","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.dsx.2025.103209_bib86","first-page":"21","article-title":"Noninvasive methods for assessing liver fibrosis and steatosis","volume":"20","author":"Kazi","year":"2024","journal-title":"Gastroenterol Hepatol"},{"key":"10.1016\/j.dsx.2025.103209_bib87","doi-asserted-by":"crossref","first-page":"goae024","DOI":"10.1093\/gastro\/goae024","article-title":"Noninvasive tests for liver fibrosis in 2024: are there different scales for different diseases?","volume":"12","author":"Lai","year":"2024","journal-title":"Gastroenterol Rep (Oxf)"},{"issue":"4","key":"10.1016\/j.dsx.2025.103209_bib88","article-title":"Embedding assessment of liver fibrosis into routine diabetic review in primary care","volume":"3","author":"Mansour","year":"2021","journal-title":"JHEP Rep"},{"issue":"1","key":"10.1016\/j.dsx.2025.103209_bib89","doi-asserted-by":"crossref","DOI":"10.1016\/j.jceh.2024.102378","article-title":"Visceral fat and diabetes: associations with liver fibrosis in metabolic dysfunction-associated steatotic liver disease","volume":"15","author":"Kumar","year":"2025","journal-title":"J Clin Exp Hepatol"},{"key":"10.1016\/j.dsx.2025.103209_bib90","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.615978","article-title":"Liver fibrosis in non-alcoholic fatty liver disease: from liver biopsy to non-invasive biomarkers in diagnosis and treatment","volume":"8","author":"Heyens","year":"2021","journal-title":"Front Med"},{"issue":"11","key":"10.1016\/j.dsx.2025.103209_bib91","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1016\/j.cgh.2021.12.034","article-title":"Low accuracy of FIB-4 and NAFLD fibrosis scores for screening for liver fibrosis in the population","volume":"20","author":"Graupera","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.dsx.2025.103209_bib92","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.jhep.2021.05.025","article-title":"EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update","volume":"75","year":"2021","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.dsx.2025.103209_bib93","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1053\/j.gastro.2020.12.003","article-title":"The association of histologic and noninvasive tests with adverse clinical and patient-reported outcomes in patients with advanced fibrosis due to nonalcoholic steatohepatitis","volume":"160","author":"Younossi","year":"2021","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.dsx.2025.103209_bib94","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1053\/j.gastro.2023.06.013","article-title":"AGA clinical practice update on the role of noninvasive biomarkers in the evaluation and management of nonalcoholic fatty liver disease: expert review","volume":"165","author":"Wattacheril","year":"2023","journal-title":"Gastroenterology"},{"issue":"8","key":"10.1016\/j.dsx.2025.103209_bib95","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1016\/j.cgh.2023.03.042","article-title":"Noninvasive assessment of liver fibrosis in NAFLD","volume":"21","author":"Sanyal","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.dsx.2025.103209_bib96","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/ajg.2016.453","article-title":"Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis","volume":"112","author":"McPherson","year":"2017","journal-title":"Am J Gastroenterol"},{"issue":"9","key":"10.1016\/j.dsx.2025.103209_bib97","first-page":"605","article-title":"Fibroscan (transient elastography) for the measurement of liver fibrosis","volume":"8","author":"Afdhal","year":"2012","journal-title":"Gastroenterol Hepatol"},{"issue":"32","key":"10.1016\/j.dsx.2025.103209_bib98","doi-asserted-by":"crossref","first-page":"7236","DOI":"10.3748\/wjg.v22.i32.7236","article-title":"Transient elastography (FibroScan((R))) with controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease - where do we stand?","volume":"22","author":"Mikolasevic","year":"2016","journal-title":"World J Gastroenterol"},{"issue":"5","key":"10.1016\/j.dsx.2025.103209_bib99","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.nut.2004.01.020","article-title":"Insulin resistance syndrome (metabolic syndrome) and obesity in Asian Indians: evidence and implications","volume":"20","author":"Misra","year":"2004","journal-title":"Nutrition"},{"issue":"11","key":"10.1016\/j.dsx.2025.103209_bib100","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/j.jdiacomp.2018.08.001","article-title":"Body fat, metabolic syndrome and hyperglycemia in South Asians","volume":"32","author":"Misra","year":"2018","journal-title":"J Diabet Complicat"},{"issue":"11","key":"10.1016\/j.dsx.2025.103209_bib101","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1002\/oby.23263","article-title":"Type 2 diabetes mellitus increases the risk of hepatic fibrosis in individuals with obesity and nonalcoholic fatty liver disease","volume":"29","author":"Barb","year":"2021","journal-title":"Obesity"},{"issue":"1","key":"10.1016\/j.dsx.2025.103209_bib102","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7570\/jomes22023","article-title":"Metabolic syndrome: a warning sign of liver fibrosis","volume":"31","author":"Seo","year":"2022","journal-title":"J Obes Metab Syndr"},{"key":"10.1016\/j.dsx.2025.103209_bib103","doi-asserted-by":"crossref","first-page":"56","DOI":"10.12688\/f1000research.21918.1","article-title":"Dyslipidemia as a risk factor for liver fibrosis progression in a multicentric population with non-alcoholic steatohepatitis","volume":"9","author":"Mendez-Sanchez","year":"2020","journal-title":"F1000Res"},{"issue":"2","key":"10.1016\/j.dsx.2025.103209_bib104","doi-asserted-by":"crossref","DOI":"10.1016\/j.aohep.2022.100892","article-title":"Blood pressure stratification for predicting liver fibrosis risk in metabolic dysfunction associated fatty liver disease","volume":"28","author":"Liu","year":"2023","journal-title":"Ann Hepatol"},{"issue":"2","key":"10.1016\/j.dsx.2025.103209_bib105","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/hep.31608","article-title":"Hepatic fibrosis associates with multiple cardiometabolic disease risk factors: the framingham heart study","volume":"73","author":"Long","year":"2021","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.dsx.2025.103209_bib106","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1097\/HEP.0000000000000432","article-title":"Duration of type 2 diabetes and liver-related events in nonalcoholic fatty liver disease: a landmark analysis","volume":"78","author":"Zhang","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.dsx.2025.103209_bib107","doi-asserted-by":"crossref","first-page":"293","DOI":"10.2147\/IJGM.S395948","article-title":"Factors associated with liver fibrosis in Chinese patients with type 2 diabetes mellitus and non-alcoholic fatty liver disease","volume":"16","author":"Luo","year":"2023","journal-title":"Int J Gen Med"},{"issue":"3","key":"10.1016\/j.dsx.2025.103209_bib108","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1002\/hep.31806","article-title":"Glycemic control predicts severity of hepatocyte ballooning and hepatic fibrosis in nonalcoholic fatty liver disease","volume":"74","author":"Alexopoulos","year":"2021","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.dsx.2025.103209_bib109","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","year":"2024","journal-title":"J Hepatol"},{"issue":"11","key":"10.1016\/j.dsx.2025.103209_bib110","doi-asserted-by":"crossref","first-page":"3204","DOI":"10.1111\/jgh.15595","article-title":"Low skeletal muscle mass is associated with liver fibrosis in individuals with type 2 diabetes and nonalcoholic fatty liver disease","volume":"36","author":"Kuchay","year":"2021","journal-title":"J Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.dsx.2025.103209_bib111","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/cld.900","article-title":"Association of sarcopenia and NAFLD: an overview","volume":"16","author":"Li","year":"2020","journal-title":"Clin Liver Dis"},{"issue":"12","key":"10.1016\/j.dsx.2025.103209_bib112","doi-asserted-by":"crossref","DOI":"10.1016\/j.dsx.2023.102902","article-title":"Prevalence of sarcopenia and its determinants in people with type 2 diabetes: experience from a tertiary care hospital in north India","volume":"17","author":"Shahi","year":"2023","journal-title":"Diabetes Metabol Syndr"},{"issue":"6","key":"10.1016\/j.dsx.2025.103209_bib113","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1016\/j.dsx.2019.11.009","article-title":"Dietary proteins, metabolic syndrome, and sarcopenia: focus on Asian Indians","volume":"13","author":"Gulati","year":"2019","journal-title":"Diabetes Metabol Syndr"},{"issue":"5","key":"10.1016\/j.dsx.2025.103209_bib114","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s41999-020-00332-z","article-title":"Diagnostic cut-offs, prevalence, and biochemical predictors of sarcopenia in healthy Indian adults: the Sarcopenia-Chandigarh Urban Bone Epidemiological Study (Sarco-CUBES)","volume":"11","author":"Pal","year":"2020","journal-title":"Eur Geriatr Med"},{"key":"10.1016\/j.dsx.2025.103209_bib115","doi-asserted-by":"crossref","first-page":"332","DOI":"10.3389\/fendo.2020.00332","article-title":"Health consequences of sarcopenic obesity: a narrative review","volume":"11","author":"Roh","year":"2020","journal-title":"Front Endocrinol"},{"issue":"3","key":"10.1016\/j.dsx.2025.103209_bib116","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1007\/s13679-024-00571-2","article-title":"Sarcopenic obesity and cardiovascular disease: an overlooked but high-risk syndrome","volume":"13","author":"Mirzai","year":"2024","journal-title":"Curr Obes Rep"},{"issue":"9","key":"10.1016\/j.dsx.2025.103209_bib117","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/j.clnu.2024.07.006","article-title":"The prevalence and effects of sarcopenia in patients with metabolic dysfunction-associated steatotic liver disease (MASLD): a systematic review and meta-analysis","volume":"43","author":"Li","year":"2024","journal-title":"Clin Nutr"},{"issue":"3","key":"10.1016\/j.dsx.2025.103209_bib118","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.jamda.2019.12.012","article-title":"Asian working group for sarcopenia: 2019 consensus update on sarcopenia diagnosis and treatment","volume":"21","author":"Chen","year":"2020","journal-title":"J Am Med Dir Assoc"},{"issue":"1","key":"10.1016\/j.dsx.2025.103209_bib119","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s12664-021-01207-2","article-title":"Normative values of skeletal muscle indices for nutritional assessment and implications on definition of sarcopenia in Indian adult population","volume":"41","author":"Choudhary","year":"2022","journal-title":"Indian J Gastroenterol"},{"issue":"11","key":"10.1016\/j.dsx.2025.103209_bib120","doi-asserted-by":"crossref","DOI":"10.1016\/j.dsx.2022.102654","article-title":"Global research in sarcopenia: high-cited papers, research institutions, funding agencies and collaborations, 1993-2022","volume":"16","author":"Vaishya","year":"2022","journal-title":"Diabetes Metabol Syndr"},{"issue":"12","key":"10.1016\/j.dsx.2025.103209_bib121","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/S2213-8587(18)30204-3","article-title":"Epidemiology and determinants of type 2 diabetes in south Asia","volume":"6","author":"Hills","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"10.1016\/j.dsx.2025.103209_bib122","doi-asserted-by":"crossref","first-page":"871","DOI":"10.4254\/wjh.v16.i6.871","article-title":"Sarcopenia and metabolic dysfunction associated steatotic liver disease: time to address both","volume":"16","author":"Wong","year":"2024","journal-title":"World J Hepatol"},{"issue":"5","key":"10.1016\/j.dsx.2025.103209_bib123","doi-asserted-by":"crossref","first-page":"626","DOI":"10.5009\/gnl19126","article-title":"Sarcopenia is independently associated with the degree of liver fibrosis in patients with type 2 diabetes mellitus","volume":"14","author":"Sung","year":"2020","journal-title":"Gut Liver"},{"issue":"17","key":"10.1016\/j.dsx.2025.103209_bib124","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12175499","article-title":"Sarcopenia in type 2 diabetes mellitus: study of the modifiable risk factors involved","volume":"12","author":"Sravya","year":"2023","journal-title":"J Clin Med"},{"issue":"2","key":"10.1016\/j.dsx.2025.103209_bib125","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines11020468","article-title":"Non-alcoholic fatty liver disease (NAFLD), type 2 diabetes, and non-viral hepatocarcinoma: pathophysiological mechanisms and new therapeutic strategies","volume":"11","author":"Vetrano","year":"2023","journal-title":"Biomedicines"},{"issue":"2","key":"10.1016\/j.dsx.2025.103209_bib126","doi-asserted-by":"crossref","first-page":"343","DOI":"10.3748\/wjg.v29.i2.343","article-title":"Hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis","volume":"29","author":"Tovo","year":"2023","journal-title":"World J Gastroenterol"},{"issue":"1","key":"10.1016\/j.dsx.2025.103209_bib127","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jceh.2019.09.007","article-title":"2019 update of Indian national association for study of the liver consensus on prevention, diagnosis, and management of hepatocellular carcinoma in India: the puri II recommendations","volume":"10","author":"Kumar","year":"2020","journal-title":"J Clin Exp Hepatol"},{"issue":"6","key":"10.1016\/j.dsx.2025.103209_bib128","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12061422","article-title":"Surveillance for hepatocellular carcinoma in patients with non-alcoholic fatty liver disease: universal or selective?","volume":"12","author":"Plaz Torres","year":"2020","journal-title":"Cancers"},{"issue":"13","key":"10.1016\/j.dsx.2025.103209_bib129","doi-asserted-by":"crossref","first-page":"270","DOI":"10.21037\/atm.2017.04.41","article-title":"Type 2 diabetes mellitus and risk of hepatocellular carcinoma: spotlight on nonalcoholic fatty liver disease","volume":"5","author":"Mantovani","year":"2017","journal-title":"Ann Transl Med"},{"issue":"2","key":"10.1016\/j.dsx.2025.103209_bib130","doi-asserted-by":"crossref","first-page":"64","DOI":"10.4103\/sjg.sjg_636_20","article-title":"Surveillance for hepatocellular carcinoma in patients with advanced liver fibrosis","volume":"27","author":"Sangiovanni","year":"2021","journal-title":"Saudi J Gastroenterol"},{"issue":"1","key":"10.1016\/j.dsx.2025.103209_bib131","doi-asserted-by":"crossref","DOI":"10.3390\/jpm14010061","article-title":"Non-pharmacological approach to diet and exercise in metabolic-associated fatty liver disease: bridging the gap between research and clinical practice","volume":"14","author":"Ali","year":"2024","journal-title":"J Personalized Med"},{"issue":"4","key":"10.1016\/j.dsx.2025.103209_bib132","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.jhep.2017.05.016","article-title":"Treatment of NAFLD with diet, physical activity and exercise","volume":"67","author":"Romero-Gomez","year":"2017","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.dsx.2025.103209_bib133","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41430-021-01067-1","article-title":"Heterogeneity of Dietary practices in India: current status and implications for the prevention and control of type 2 diabetes","volume":"77","author":"Sachdev","year":"2023","journal-title":"Eur J Clin Nutr"},{"issue":"6","key":"10.1016\/j.dsx.2025.103209_bib134","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1089\/dia.2010.0198","article-title":"Consensus dietary guidelines for healthy living and prevention of obesity, the metabolic syndrome, diabetes, and related disorders in Asian Indians","volume":"13","author":"Misra","year":"2011","journal-title":"Diabetes Technol Therapeut"},{"issue":"7","key":"10.1016\/j.dsx.2025.103209_bib135","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1038\/ejcn.2017.92","article-title":"Abdominal obesity and type 2 diabetes in Asian Indians: dietary strategies including edible oils, cooking practices and sugar intake","volume":"71","author":"Gulati","year":"2017","journal-title":"Eur J Clin Nutr"},{"issue":"5","key":"10.1016\/j.dsx.2025.103209_bib136","doi-asserted-by":"crossref","first-page":"438","DOI":"10.2174\/1573399812666160811165712","article-title":"Dietary fats and oils in India","volume":"13","author":"Gulati","year":"2017","journal-title":"Curr Diabetes Rev"},{"issue":"11 Suppl 1","key":"10.1016\/j.dsx.2025.103209_bib137","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1210\/jc.2008-1595","article-title":"Obesity and the metabolic syndrome in developing countries","volume":"93","author":"Misra","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.dsx.2025.103209_bib138","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.clnesp.2024.02.001","article-title":"Dietary pattern associated with non-alcoholic fatty liver disease (NAFLD) in non-diabetic adult patients: a case control study","volume":"60","author":"Chaturvedi","year":"2024","journal-title":"Clin Nutr ESPEN"},{"issue":"5","key":"10.1016\/j.dsx.2025.103209_bib139","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1002\/hep.24242","article-title":"Randomized comparison of reduced fat and reduced carbohydrate hypocaloric diets on intrahepatic fat in overweight and obese human subjects","volume":"53","author":"Haufe","year":"2011","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.dsx.2025.103209_bib140","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","article-title":"The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"71","author":"Younossi","year":"2019","journal-title":"J Hepatol"},{"issue":"11","key":"10.1016\/j.dsx.2025.103209_bib141","doi-asserted-by":"crossref","DOI":"10.1111\/ijpo.13163","article-title":"Effect of Indo-Mediterranean diet versus calorie-restricted diet in children with non-alcoholic fatty liver disease: a pilot randomized control trial","volume":"19","author":"Deshmukh","year":"2024","journal-title":"Pediatr Obes"},{"issue":"10","key":"10.1016\/j.dsx.2025.103209_bib142","first-page":"1245","article-title":"Effect of soy consumption on liver enzymes, lipid profile, anthropometry indices, and oxidative stress in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis of clinical trials","volume":"23","author":"Zarei","year":"2020","journal-title":"Iran J Basic Med Sci"},{"issue":"10","key":"10.1016\/j.dsx.2025.103209_bib143","doi-asserted-by":"crossref","DOI":"10.3390\/nu15102394","article-title":"Effect of nut consumption on nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"15","author":"Pan","year":"2023","journal-title":"Nutrients"},{"issue":"6","key":"10.1016\/j.dsx.2025.103209_bib144","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1093\/ajcn\/nqy204","article-title":"A 12-wk whole-grain wheat intervention protects against hepatic fat: the Graandioos study, a randomized trial in overweight subjects","volume":"108","author":"Schutte","year":"2018","journal-title":"Am J Clin Nutr"},{"issue":"1","key":"10.1016\/j.dsx.2025.103209_bib145","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1136\/gutjnl-2017-314786","article-title":"Whole grain-rich diet reduces body weight and systemic low-grade inflammation without inducing major changes of the gut microbiome: a randomised cross-over trial","volume":"68","author":"Roager","year":"2019","journal-title":"Gut"},{"issue":"5","key":"10.1016\/j.dsx.2025.103209_bib146","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1093\/advances\/nmaa029","article-title":"Fish consumption and the risk of chronic disease: an umbrella review of meta-analyses of prospective cohort studies","volume":"11","author":"Jayedi","year":"2020","journal-title":"Adv Nutr"},{"key":"10.1016\/j.dsx.2025.103209_bib147","doi-asserted-by":"crossref","DOI":"10.7189\/jogh.14.04060","article-title":"Association between processed and unprocessed red meat consumption and risk of nonalcoholic fatty liver disease: a systematic review and dose-response meta-analysis","volume":"14","author":"Zhou","year":"2024","journal-title":"J Glob Health"},{"issue":"1","key":"10.1016\/j.dsx.2025.103209_bib148","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0096102","article-title":"Fish intake and risk of liver cancer: a meta-analysis","volume":"10","author":"Huang","year":"2015","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.dsx.2025.103209_bib149","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1080\/07315724.2015.1022637","article-title":"Dairy consumption lowers systemic inflammation and liver enzymes in typically low-dairy consumers with clinical characteristics of metabolic syndrome","volume":"35","author":"Dugan","year":"2016","journal-title":"J Am Coll Nutr"},{"issue":"6","key":"10.1016\/j.dsx.2025.103209_bib150","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1089\/dia.2010.0198","article-title":"Consensus dietary guidelines for healthy living and prevention of obesity, the metabolic syndrome, diabetes, and related disorders in Asian Indians","volume":"13","author":"Misra","year":"2011","journal-title":"Diabetes Technol Therapeut"},{"issue":"19","key":"10.1016\/j.dsx.2025.103209_bib151","doi-asserted-by":"crossref","DOI":"10.1002\/mnfr.201900385","article-title":"Industrial trans fatty acids stimulate SREBP2-mediated cholesterogenesis and promote non-alcoholic fatty liver disease","volume":"63","author":"Oteng","year":"2019","journal-title":"Mol Nutr Food Res"},{"issue":"3","key":"10.1016\/j.dsx.2025.103209_bib152","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.dsx.2012.03.002","article-title":"Overview of trans fatty acids: biochemistry and health effects","volume":"5","author":"Bhardwaj","year":"2011","journal-title":"Diabetes Metabol Syndr"},{"key":"10.1016\/j.dsx.2025.103209_bib153","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.foodchem.2016.06.021","article-title":"Effect of heating\/reheating of fats\/oils, as used by Asian Indians, on trans fatty acid formation","volume":"212","author":"Bhardwaj","year":"2016","journal-title":"Food Chem"},{"issue":"2","key":"10.1016\/j.dsx.2025.103209_bib154","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.dsx.2019.01.054","article-title":"Nutrition and physical activity in Asian Indians with non-alcoholic fatty liver: a case control study","volume":"13","author":"Bhatt","year":"2019","journal-title":"Diabetes Metabol Syndr"},{"issue":"8","key":"10.1016\/j.dsx.2025.103209_bib155","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.2337\/dc18-0071","article-title":"Saturated fat is more metabolically harmful for the human liver than unsaturated fat or simple sugars","volume":"41","author":"Luukkonen","year":"2018","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1016\/j.dsx.2025.103209_bib156","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1017\/S0007114524000564","article-title":"The effects of replacing ghee with rapeseed oil on liver steatosis and enzymes, lipid profile, insulin resistance and anthropometric measurements in patients with non-alcoholic fatty liver disease: a randomised controlled clinical trial","volume":"131","author":"Maleki Sedgi","year":"2024","journal-title":"Br J Nutr"},{"issue":"1","key":"10.1016\/j.dsx.2025.103209_bib157","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1097\/MOL.0000000000000728","article-title":"Impact of ultra-processed food consumption on metabolic health","volume":"32","author":"Costa de Miranda","year":"2021","journal-title":"Curr Opin Lipidol"},{"issue":"10","key":"10.1016\/j.dsx.2025.103209_bib158","doi-asserted-by":"crossref","DOI":"10.3390\/nu15102266","article-title":"Ultra-processed food intake is associated with non-alcoholic fatty liver disease in adults: a systematic review and meta-analysis","volume":"15","author":"Henney","year":"2023","journal-title":"Nutrients"},{"key":"10.1016\/j.dsx.2025.103209_bib159","series-title":"The growth of ultra-processed foods in India: an analysis of trends, issues and policy recommendations","year":"2023"},{"key":"10.1016\/j.dsx.2025.103209_bib160","doi-asserted-by":"crossref","DOI":"10.1155\/2023\/4197955","article-title":"Effects of different vegetable oils on the nonalcoholic fatty liver disease in C57\/BL mice","volume":"2023","author":"Manca","year":"2023","journal-title":"Evid Based Complement Alternat Med"},{"issue":"4","key":"10.1016\/j.dsx.2025.103209_bib161","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1089\/dia.2013.0178","article-title":"Effect of a 6-month intervention with cooking oils containing a high concentration of monounsaturated fatty acids (olive and canola oils) compared with control oil in male Asian Indians with nonalcoholic fatty liver disease","volume":"16","author":"Nigam","year":"2014","journal-title":"Diabetes Technol Therapeut"},{"issue":"11\u201312","key":"10.1016\/j.dsx.2025.103209_bib162","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/j.nut.2016.04.006","article-title":"Supplementation with antioxidant-rich extra virgin olive oil prevents hepatic oxidative stress and reduction of desaturation capacity in mice fed a high-fat diet: effects on fatty acid composition in liver and extrahepatic tissues","volume":"32","author":"Rincon-Cervera","year":"2016","journal-title":"Nutrition"},{"issue":"4","key":"10.1016\/j.dsx.2025.103209_bib163","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/j.jhep.2011.08.018","article-title":"Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"56","author":"Parker","year":"2012","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.dsx.2025.103209_bib164","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/j.jhep.2011.12.011","article-title":"Predictors for incidence and remission of NAFLD in the general population during a seven-year prospective follow-up","volume":"56","author":"Zelber-Sagi","year":"2012","journal-title":"J Hepatol"},{"issue":"7","key":"10.1016\/j.dsx.2025.103209_bib165","doi-asserted-by":"crossref","DOI":"10.3390\/cells10071805","article-title":"Diet-Induced models of non-alcoholic fatty liver disease: food for thought on sugar, fat, and cholesterol","volume":"10","author":"Eng","year":"2021","journal-title":"Cells"},{"issue":"5","key":"10.1016\/j.dsx.2025.103209_bib166","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/nrgastro.2010.41","article-title":"The role of fructose in the pathogenesis of NAFLD and the metabolic syndrome","volume":"7","author":"Lim","year":"2010","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.dsx.2025.103209_bib167","article-title":"Burdens of type 2 diabetes and cardiovascular disease attributable to sugar-sweetened beverages in 184 countries","author":"Lara-Castor","year":"2025","journal-title":"Nat Med"},{"issue":"12","key":"10.1016\/j.dsx.2025.103209_bib168","doi-asserted-by":"crossref","first-page":"5955","DOI":"10.3390\/nu6125955","article-title":"Sugar intake, obesity, and diabetes in India","volume":"6","author":"Gulati","year":"2014","journal-title":"Nutrients"},{"issue":"7521","key":"10.1016\/j.dsx.2025.103209_bib169","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/nature13793","article-title":"Artificial sweeteners induce glucose intolerance by altering the gut microbiota","volume":"514","author":"Suez","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.dsx.2025.103209_bib170","first-page":"620","article-title":"Artificial sweeteners are related to non-alcoholic fatty liver disease: microbiota dysbiosis as a novel potential mechanism","volume":"19","author":"Emamat","year":"2020","journal-title":"EXCLI J"},{"issue":"8","key":"10.1016\/j.dsx.2025.103209_bib171","doi-asserted-by":"crossref","DOI":"10.1016\/j.dsx.2023.102829","article-title":"Non-sugar sweeteners and health outcomes in adults without diabetes: deciphering the WHO recommendations in the Indian context","volume":"17","author":"Singh","year":"2023","journal-title":"Diabetes Metabol Syndr"},{"issue":"8","key":"10.1016\/j.dsx.2025.103209_bib172","doi-asserted-by":"crossref","DOI":"10.3390\/nu15081869","article-title":"Effect of non-nutritive sweeteners on the gut microbiota","volume":"15","author":"Conz","year":"2023","journal-title":"Nutrients"},{"issue":"9","key":"10.1016\/j.dsx.2025.103209_bib173","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1007\/s13300-024-01622-6","article-title":"Effect of replacing sucrose in beverages with nonnutritive sweetener sucralose on cardiometabolic risk factors among asian Indian adults with type 2 diabetes: a 12-week randomized controlled trial","volume":"15","author":"Mohan","year":"2024","journal-title":"Diabetes Ther"},{"issue":"6","key":"10.1016\/j.dsx.2025.103209_bib174","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1016\/j.clnu.2018.11.030","article-title":"A systematic review and a dose-response meta-analysis of coffee dose and nonalcoholic fatty liver disease","volume":"38","author":"Chen","year":"2019","journal-title":"Clin Nutr"},{"issue":"10","key":"10.1016\/j.dsx.2025.103209_bib175","doi-asserted-by":"crossref","DOI":"10.3390\/nu11102364","article-title":"Tea compounds and the gut microbiome: findings from trials and mechanistic studies","volume":"11","author":"Bond","year":"2019","journal-title":"Nutrients"},{"issue":"11","key":"10.1016\/j.dsx.2025.103209_bib176","doi-asserted-by":"crossref","DOI":"10.3390\/nu11112601","article-title":"Effects of periodic fasting on fatty liver index-A prospective observational study","volume":"11","author":"Drinda","year":"2019","journal-title":"Nutrients"},{"issue":"11","key":"10.1016\/j.dsx.2025.103209_bib177","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1016\/j.cgh.2022.10.039","article-title":"Nonheavy alcohol use associates with liver fibrosis and nonalcoholic steatohepatitis in the framingham heart study","volume":"21","author":"Rice","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"11\u201312","key":"10.1016\/j.dsx.2025.103209_bib178","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1111\/apt.13828","article-title":"Mendelian randomisation suggests no beneficial effect of moderate alcohol consumption on the severity of nonalcoholic fatty liver disease","volume":"44","author":"Sookoian","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.dsx.2025.103209_bib179","doi-asserted-by":"crossref","first-page":"189","DOI":"10.4103\/psychiatry.IndianJPsychiatry_453_17","article-title":"Drinking pattern in persons with alcohol dependence with and without cirrhosis: a hospital-based comparative study","volume":"60","author":"Kakunje","year":"2018","journal-title":"Indian J Psychiatry"},{"issue":"12","key":"10.1016\/j.dsx.2025.103209_bib180","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines9121853","article-title":"The role of physical activity in nonalcoholic and metabolic dysfunction associated fatty liver disease","volume":"9","author":"von Loeffelholz","year":"2021","journal-title":"Biomedicines"},{"issue":"14","key":"10.1016\/j.dsx.2025.103209_bib181","article-title":"Physical activity protocols in non-alcoholic fatty liver disease management: a systematic review of randomized clinical trials and animal models","volume":"11","author":"Barron-Cabrera","year":"2023","journal-title":"Healthcare (Basel)"},{"issue":"1","key":"10.1016\/j.dsx.2025.103209_bib182","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.cgh.2016.07.031","article-title":"Exercise reduces liver lipids and visceral adiposity in patients with nonalcoholic steatohepatitis in a randomized controlled trial","volume":"15","author":"Houghton","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.dsx.2025.103209_bib183","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.diabres.2015.05.033","article-title":"Volume-dependent effect of supervised exercise training on fatty liver and visceral adiposity index in subjects with type 2 diabetes the Italian Diabetes Exercise Study (IDES)","volume":"109","author":"Balducci","year":"2015","journal-title":"Diabetes Res Clin Pract"},{"issue":"8","key":"10.1016\/j.dsx.2025.103209_bib184","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1001\/jamainternmed.2016.3202","article-title":"Effects of moderate and vigorous exercise on nonalcoholic fatty liver disease: a randomized clinical trial","volume":"176","author":"Zhang","year":"2016","journal-title":"JAMA Intern Med"},{"issue":"4","key":"10.1016\/j.dsx.2025.103209_bib185","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1177\/1756283X13484078","article-title":"Prospective histopathologic evaluation of lifestyle modification in nonalcoholic fatty liver disease: a randomized trial","volume":"6","author":"Eckard","year":"2013","journal-title":"Therap Adv Gastroenterol"},{"issue":"1","key":"10.1016\/j.dsx.2025.103209_bib186","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/hep.23276","article-title":"Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis","volume":"51","author":"Promrat","year":"2010","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.dsx.2025.103209_bib187","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jhep.2016.08.023","article-title":"Aerobic vs. resistance exercise in non-alcoholic fatty liver disease: a systematic review","volume":"66","author":"Hashida","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.dsx.2025.103209_bib188","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2024.1428723","article-title":"Comparative efficacy of different exercise modalities on metabolic profiles and liver functions in non-alcoholic fatty liver disease: a network meta-analysis","volume":"15","author":"Huang","year":"2024","journal-title":"Front Physiol"},{"issue":"1","key":"10.1016\/j.dsx.2025.103209_bib189","doi-asserted-by":"crossref","first-page":"6212","DOI":"10.1038\/s41598-024-51470-4","article-title":"Effect of different exercise modalities on nonalcoholic fatty liver disease: a systematic review and network meta-analysis","volume":"14","author":"Xue","year":"2024","journal-title":"Sci Rep"},{"issue":"10019","key":"10.1016\/j.dsx.2025.103209_bib190","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.dsx.2025.103209_bib191","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/hepr.12351","article-title":"Pilot study of liraglutide effects in non-alcoholic steatohepatitis and non-alcoholic fatty liver disease with glucose intolerance in Japanese patients (LEAN-J)","volume":"45","author":"Eguchi","year":"2015","journal-title":"Hepatol Res"},{"issue":"2","key":"10.1016\/j.dsx.2025.103209_bib192","first-page":"407","article-title":"Effect of liraglutide therapy on liver fat content in patients with inadequately controlled type 2 diabetes: the lira-NAFLD study","volume":"102","author":"Petit","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"10.1016\/j.dsx.2025.103209_bib193","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1111\/dme.13697","article-title":"Dulaglutide decreases plasma aminotransferases in people with Type 2 diabetes in a pattern consistent with liver fat reduction: a post hoc analysis of the AWARD programme","volume":"35","author":"Cusi","year":"2018","journal-title":"Diabet Med"},{"issue":"3","key":"10.1016\/j.dsx.2025.103209_bib194","doi-asserted-by":"crossref","first-page":"202","DOI":"10.2337\/ds16-0026","article-title":"Glucagon-like peptide 1 receptor agonists for type 2 diabetes","volume":"30","author":"Hinnen","year":"2017","journal-title":"Diabetes Spectr"},{"issue":"5","key":"10.1016\/j.dsx.2025.103209_bib195","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1002\/hep.23569","article-title":"Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway","volume":"51","author":"Gupta","year":"2010","journal-title":"Hepatology"},{"issue":"9","key":"10.1016\/j.dsx.2025.103209_bib196","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0025269","article-title":"GLP-1 analogs reduce hepatocyte steatosis and improve survival by enhancing the unfolded protein response and promoting macroautophagy","volume":"6","author":"Sharma","year":"2011","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.dsx.2025.103209_bib197","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.dsx.2025.103209_bib198","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1007\/s00125-020-05265-7","article-title":"Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial)","volume":"63","author":"Kuchay","year":"2020","journal-title":"Diabetologia"},{"key":"10.1016\/j.dsx.2025.103209_bib199","doi-asserted-by":"crossref","DOI":"10.1007\/s40618-024-02466-4","article-title":"Comparative outcomes of systemic diseases in people with type 2 diabetes, or obesity alone treated with and without GLP-1 receptor agonists: a retrospective cohort study from the Global Collaborative Network : author list","author":"Nassar","year":"2024","journal-title":"J Endocrinol Investig"},{"key":"10.1016\/j.dsx.2025.103209_bib200","unstructured":"ESSENCE trial results (Company Announcement), https:\/\/www.novonordisk.com\/news-and-media\/news-and-ir-materials\/news-details.html?id=171971."},{"issue":"4","key":"10.1016\/j.dsx.2025.103209_bib201","doi-asserted-by":"crossref","first-page":"819","DOI":"10.2337\/dc21-1953","article-title":"Glucagon-like peptide 1 receptor agonists and sodium-glucose cotransporter 2 inhibitors and risk of nonalcoholic fatty liver disease among patients with type 2 diabetes","volume":"45","author":"Pradhan","year":"2022","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1016\/j.dsx.2025.103209_bib202","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1001\/jamainternmed.2024.4661","article-title":"GLP-1 receptor agonists and risk for cirrhosis and related complications in patients with metabolic dysfunction-associated steatotic liver disease","volume":"184","author":"Kanwal","year":"2024","journal-title":"JAMA Intern Med"},{"issue":"1","key":"10.1016\/j.dsx.2025.103209_bib203","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/dom.14831","article-title":"Tirzepatide for the treatment of adults with type 2 diabetes: an endocrine perspective","volume":"25","author":"De Block","year":"2023","journal-title":"Diabetes Obes Metab"},{"issue":"22","key":"10.1016\/j.dsx.2025.103209_bib204","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1001\/jama.2023.24539","article-title":"FDA green-lights tirzepatide, marketed as zepbound, for chronic weight management","volume":"330","author":"Abbasi","year":"2023","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.dsx.2025.103209_bib205","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1056\/NEJMoa2401943","article-title":"Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis","volume":"391","author":"Loomba","year":"2024","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.dsx.2025.103209_bib206","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.2337\/dc20-2151","article-title":"Effects of cotadutide on metabolic and hepatic parameters in adults with overweight or obesity and type 2 diabetes: a 54-week randomized phase 2b study","volume":"44","author":"Nahra","year":"2021","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.dsx.2025.103209_bib207","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.jhep.2023.05.013","article-title":"A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease","volume":"79","author":"Romero-Gomez","year":"2023","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.dsx.2025.103209_bib208","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa2401755","article-title":"A phase 2 randomized trial of survodutide in MASH and fibrosis","volume":"391","author":"Sanyal","year":"2024","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.dsx.2025.103209_bib209","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa2301972","article-title":"Triple-Hormone-receptor agonist retatrutide for obesity - a phase 2 trial","volume":"389","author":"Jastreboff","year":"2023","journal-title":"N Engl J Med"},{"issue":"10401","key":"10.1016\/j.dsx.2025.103209_bib210","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0140-6736(23)01053-X","article-title":"Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA","volume":"402","author":"Rosenstock","year":"2023","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.dsx.2025.103209_bib211","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.2337\/dc18-0165","article-title":"Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT trial)","volume":"41","author":"Kuchay","year":"2018","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1016\/j.dsx.2025.103209_bib212","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1007\/s00125-018-4702-3","article-title":"Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME(R) trial","volume":"61","author":"Sattar","year":"2018","journal-title":"Diabetologia"},{"issue":"5","key":"10.1016\/j.dsx.2025.103209_bib213","doi-asserted-by":"crossref","first-page":"931","DOI":"10.2337\/dc18-1569","article-title":"The SGLT2 inhibitor dapagliflozin reduces liver fat but does not affect tissue insulin sensitivity: a randomized, double-blind, placebo-controlled study with 8-week treatment in type 2 diabetes patients","volume":"42","author":"Latva-Rasku","year":"2019","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.dsx.2025.103209_bib214","doi-asserted-by":"crossref","first-page":"e2267","DOI":"10.1210\/clinem\/dgac138","article-title":"Dapagliflozin improves body fat patterning, and hepatic and pancreatic fat in patients with type 2 diabetes in north India","volume":"107","author":"Ghosh","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.dsx.2025.103209_bib215","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.diabet.2019.01.008","article-title":"Beneficial effects of SGLT2 inhibitors on fatty liver in type 2 diabetes: a common comorbidity associated with severe complications","volume":"45","author":"Scheen","year":"2019","journal-title":"Diabetes Metab"},{"issue":"2","key":"10.1016\/j.dsx.2025.103209_bib216","doi-asserted-by":"crossref","first-page":"398","DOI":"10.2337\/dc21-1136","article-title":"Empagliflozin improves insulin sensitivity of the hypothalamus in humans with prediabetes: a randomized, double-blind, placebo-controlled, phase 2 trial","volume":"45","author":"Kullmann","year":"2022","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.dsx.2025.103209_bib217","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/hep4.1019","article-title":"Effects of a sodium-glucose cotransporter 2 inhibitor in nonalcoholic fatty liver disease complicated by diabetes mellitus: Preliminary prospective study based on serial liver biopsies","volume":"1","author":"Akuta","year":"2017","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.dsx.2025.103209_bib218","doi-asserted-by":"crossref","first-page":"835","DOI":"10.2147\/DMSO.S184767","article-title":"Efficacy and safety of canagliflozin in type 2 diabetes mellitus patients with biopsy-proven nonalcoholic steatohepatitis classified as stage 1-3 fibrosis","volume":"11","author":"Seko","year":"2018","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"2","key":"10.1016\/j.dsx.2025.103209_bib219","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s10620-019-5477-1","article-title":"Empagliflozin for the treatment of nonalcoholic steatohepatitis in patients with type 2 diabetes mellitus","volume":"65","author":"Lai","year":"2020","journal-title":"Dig Dis Sci"},{"issue":"8","key":"10.1016\/j.dsx.2025.103209_bib220","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1111\/dom.15632","volume":"26","author":"Shikamura","year":"2024","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"10.1016\/j.dsx.2025.103209_bib221","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1001\/jamainternmed.2023.8029","article-title":"Outcomes of various classes of oral antidiabetic drugs on nonalcoholic fatty liver disease","volume":"184","author":"Jang","year":"2024","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.dsx.2025.103209_bib222","doi-asserted-by":"crossref","DOI":"10.2337\/dc24-1903","article-title":"Glucagon-like peptide 1 receptor agonists and sodium-glucose cotransporter 2 inhibitors and the prevention of cirrhosis among patients with type 2 diabetes","author":"Pradhan","year":"2025","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1016\/j.dsx.2025.103209_bib223","doi-asserted-by":"crossref","DOI":"10.1111\/dme.15437","article-title":"Glucose-lowering drugs and liver-related outcomes among individuals with type 2 diabetes: a systematic review of longitudinal population-based studies","volume":"41","author":"Khanmohammadi","year":"2024","journal-title":"Diabet Med"},{"key":"10.1016\/j.dsx.2025.103209_bib224","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.clnesp.2023.07.013","article-title":"Sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes mellitus and moderate to severe hepatic fibrosis: a retrospective study","volume":"57","author":"Tyagi","year":"2023","journal-title":"Clin Nutr ESPEN"},{"issue":"12","key":"10.1016\/j.dsx.2025.103209_bib225","first-page":"62","article-title":"SGLT2i as a first-line antihyperglycemic in the management of type 2 diabetes in the context of Indians: a systematic review and consensus","volume":"71","author":"Singh","year":"2023","journal-title":"J Assoc Phys India"},{"issue":"8","key":"10.1016\/j.dsx.2025.103209_bib226","doi-asserted-by":"crossref","DOI":"10.1016\/j.dsx.2022.102580","article-title":"Sodium-glucose cotransporter-2 inhibitors as first-line pharmacological therapy for type 2 diabetes?","volume":"16","author":"Kuchay","year":"2022","journal-title":"Diabetes Metabol Syndr"},{"issue":"3","key":"10.1016\/j.dsx.2025.103209_bib227","doi-asserted-by":"crossref","first-page":"880","DOI":"10.2337\/diabetes.54.3.880","article-title":"Thiazolidinediones upregulate fatty acid uptake and oxidation in adipose tissue of diabetic patients","volume":"54","author":"Boden","year":"2005","journal-title":"Diabetes"},{"issue":"8","key":"10.1016\/j.dsx.2025.103209_bib228","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/90984","article-title":"The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity","volume":"7","author":"Yamauchi","year":"2001","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.dsx.2025.103209_bib229","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1210\/jc.2006-1268","article-title":"Review: peroxisome proliferator-activated receptor gamma and adipose tissue--understanding obesity-related changes in regulation of lipid and glucose metabolism","volume":"92","author":"Sharma","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"issue":"18","key":"10.1016\/j.dsx.2025.103209_bib230","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis","volume":"362","author":"Sanyal","year":"2010","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.dsx.2025.103209_bib231","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.2337\/dc19-0167","article-title":"Role of vitamin E for nonalcoholic steatohepatitis in patients with type 2 diabetes: a randomized controlled trial","volume":"42","author":"Bril","year":"2019","journal-title":"Diabetes Care"},{"issue":"22","key":"10.1016\/j.dsx.2025.103209_bib232","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1056\/NEJMoa060326","article-title":"A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis","volume":"355","author":"Belfort","year":"2006","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.dsx.2025.103209_bib233","doi-asserted-by":"crossref","first-page":"305","DOI":"10.7326\/M15-1774","article-title":"Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial","volume":"165","author":"Cusi","year":"2016","journal-title":"Ann Intern Med"},{"issue":"4","key":"10.1016\/j.dsx.2025.103209_bib234","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1053\/j.gastro.2008.06.047","article-title":"Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis","volume":"135","author":"Aithal","year":"2008","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.dsx.2025.103209_bib235","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.dsx.2025.103209_bib236","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1007\/s00125-016-3902-y","article-title":"EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease","volume":"59","year":"2016","journal-title":"Diabetologia"},{"issue":"Suppl 1","key":"10.1016\/j.dsx.2025.103209_bib237","doi-asserted-by":"crossref","first-page":"S90","DOI":"10.2337\/dc19-S009","article-title":"Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2019","volume":"42","author":"American Diabetes","year":"2019","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.dsx.2025.103209_bib238","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.aohep.2020.09.006","article-title":"Latin American Association for the study of the liver (ALEH) practice guidance for the diagnosis and treatment of non-alcoholic fatty liver disease","volume":"19","author":"Arab","year":"2020","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.dsx.2025.103209_bib239","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2021.174076","article-title":"Effects of SGLT2 inhibitor ipragliflozin alone and combined with pioglitazone on fluid retention in type 2 diabetic mice with NASH","volume":"901","author":"Tahara","year":"2021","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"10.1016\/j.dsx.2025.103209_bib240","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.aohep.2019.10.005","article-title":"Metformin in the prevention of hepatocellular carcinoma in diabetic patients: a systematic review","volume":"19","author":"Cunha","year":"2020","journal-title":"Ann Hepatol"},{"issue":"6","key":"10.1016\/j.dsx.2025.103209_bib241","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1002\/hep.27199","article-title":"Continuation of metformin use after a diagnosis of cirrhosis significantly improves survival of patients with diabetes","volume":"60","author":"Zhang","year":"2014","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.dsx.2025.103209_bib242","doi-asserted-by":"crossref","first-page":"141","DOI":"10.3748\/wjg.v23.i1.141","article-title":"Sitagliptin in patients with non-alcoholic steatohepatitis: a randomized, placebo-controlled trial","volume":"23","author":"Joy","year":"2017","journal-title":"World J Gastroenterol"},{"issue":"2","key":"10.1016\/j.dsx.2025.103209_bib243","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.jhep.2016.04.021","article-title":"Sitagliptin vs. placebo for non-alcoholic fatty liver disease: a randomized controlled trial","volume":"65","author":"Cui","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.dsx.2025.103209_bib244","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2022.937554","article-title":"A randomized triple-blind controlled clinical trial evaluation of sitagliptin in the treatment of patients with non-alcoholic fatty liver diseases without diabetes","volume":"9","author":"Doustmohammadian","year":"2022","journal-title":"Front Med"},{"issue":"2","key":"10.1016\/j.dsx.2025.103209_bib245","first-page":"240","article-title":"Effects of sitagliptin in diabetic patients with nonalcoholic steatohepatitis","volume":"75","author":"Yilmaz","year":"2012","journal-title":"Acta Gastroenterol Belg"},{"key":"10.1016\/j.dsx.2025.103209_bib246","first-page":"23","article-title":"Effect of sitagliptin on hepatic histological activity and fibrosis of nonalcoholic steatohepatitis patients: a 1-year randomized control trial","volume":"10","author":"Alam","year":"2018","journal-title":"Hepat Med"},{"issue":"6","key":"10.1016\/j.dsx.2025.103209_bib247","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.dsx.2025.103209_bib248","doi-asserted-by":"crossref","DOI":"10.1016\/j.dsx.2024.103034","article-title":"Intrahepatic hypothyroidism in MASLD: role of liver-specific thyromimetics including resmetirom","volume":"18","author":"Kuchay","year":"2024","journal-title":"Diabetes Metabol Syndr"},{"issue":"7","key":"10.1016\/j.dsx.2025.103209_bib249","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinre.2023.102174","article-title":"Effects of saroglitazar in the treatment of non-alcoholic fatty liver disease or non-alcoholic steatohepatitis: a systematic review and meta-analysis","volume":"47","author":"Bandyopadhyay","year":"2023","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"5","key":"10.1016\/j.dsx.2025.103209_bib250","doi-asserted-by":"crossref","DOI":"10.1016\/j.jceh.2024.101398","article-title":"A prospective randomised comparative four-arm intervention study of efficacy and safety of saroglitazar and vitamin E in patients with non-alcoholic fatty liver disease (NAFLD)\/Non-alcoholic steatohepatitis (NASH)-SVIN TRIAL","volume":"14","author":"Mir","year":"2024","journal-title":"J Clin Exp Hepatol"},{"issue":"3","key":"10.1016\/j.dsx.2025.103209_bib251","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/jgh3.12878","article-title":"Efficacy and safety of saroglitazar in real-world patients of non-alcoholic fatty liver disease with or without diabetes including compensated cirrhosis: a tertiary care center experience","volume":"7","author":"Chaudhuri","year":"2023","journal-title":"JGH Open"},{"issue":"2","key":"10.1016\/j.dsx.2025.103209_bib252","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s40261-022-01245-4","article-title":"Comment on: \"efficacy and safety of saroglitazar in patients with cardiometabolic diseases: a systematic review and meta-analysis of randomized controlled trials\"","volume":"43","author":"Dutta","year":"2023","journal-title":"Clin Drug Investig"},{"issue":"6","key":"10.1016\/j.dsx.2025.103209_bib253","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1016\/j.dsx.2020.08.039","article-title":"Efficacy and safety of saroglitazar in managing hypertriglyceridemia in type-2 diabetes: a meta-analysis","volume":"14","author":"Dutta","year":"2020","journal-title":"Diabetes Metabol Syndr"},{"key":"10.1016\/j.dsx.2025.103209_bib254","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2020.101710","article-title":"Vitamin E treatment in NAFLD patients demonstrates that oxidative stress drives steatosis through upregulation of de-novo lipogenesis","volume":"37","author":"Podszun","year":"2020","journal-title":"Redox Biol"},{"issue":"6","key":"10.1016\/j.dsx.2025.103209_bib255","doi-asserted-by":"crossref","first-page":"927","DOI":"10.14309\/ajg.0000000000001726","article-title":"Dietary vitamin E intake is associated with a reduced risk of developing digestive diseases and nonalcoholic fatty liver disease","volume":"117","author":"Scorletti","year":"2022","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"10.1016\/j.dsx.2025.103209_bib256","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1002\/hep.30368","article-title":"Vitamin E improves transplant-free survival and hepatic decompensation among patients with nonalcoholic steatohepatitis and advanced fibrosis","volume":"71","author":"Vilar-Gomez","year":"2020","journal-title":"Hepatology"},{"issue":"12","key":"10.1016\/j.dsx.2025.103209_bib257","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1111\/jgh.16723","article-title":"Vitamin E improves serum markers and histology in adults with metabolic dysfunction-associated steatotic liver disease: systematic review and meta-analysis","volume":"39","author":"Chee","year":"2024","journal-title":"J Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.dsx.2025.103209_bib258","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1053\/j.gastro.2013.05.042","article-title":"Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease","volume":"145","author":"Mudaliar","year":"2013","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.dsx.2025.103209_bib259","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000037271","article-title":"The effect and safety of obeticholic acid for patients with nonalcoholic steatohepatitis: a systematic review and meta-analysis of randomized controlled trials","volume":"103","author":"Zhao","year":"2024","journal-title":"Medicine (Baltim)"},{"issue":"5","key":"10.1016\/j.dsx.2025.103209_bib260","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/j.jhep.2023.07.014","article-title":"Results from a new efficacy and safety analysis of the REGENERATE trial of obeticholic acid for treatment of pre-cirrhotic fibrosis due to non-alcoholic steatohepatitis","volume":"79","author":"Sanyal","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.dsx.2025.103209_bib261","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173616","article-title":"Systematic review and meta-analysis of randomized controlled trials on the effects of obeticholic acid on the blood lipid profile: insights into liver disorders and liver cancer","volume":"889","author":"Guan","year":"2020","journal-title":"Eur J Pharmacol"},{"issue":"17","key":"10.1016\/j.dsx.2025.103209_bib262","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2036205","article-title":"A randomized, controlled trial of the pan-PPAR agonist lanifibranor in NASH","volume":"385","author":"Francque","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dsx.2025.103209_bib263","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2024.12.045","article-title":"Pan-PPAR agonist lanifibranor improves insulin resistance and hepatic steatosis in patients with T2D and MASLD","author":"Barb","year":"2025","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.dsx.2025.103209_bib264","doi-asserted-by":"crossref","first-page":"3962","DOI":"10.1038\/s41467-024-47919-9","article-title":"The pan-PPAR agonist lanifibranor improves cardiometabolic health in patients with metabolic dysfunction-associated steatohepatitis","volume":"15","author":"Cooreman","year":"2024","journal-title":"Nat Commun"},{"issue":"3","key":"10.1016\/j.dsx.2025.103209_bib265","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1002\/hep.20092","article-title":"Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial","volume":"39","author":"Lindor","year":"2004","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.dsx.2025.103209_bib266","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.jhep.2010.08.030","article-title":"A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis","volume":"54","author":"Ratziu","year":"2011","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.dsx.2025.103209_bib267","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1002\/hep.23727","article-title":"High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial","volume":"52","author":"Leuschner","year":"2010","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.dsx.2025.103209_bib268","first-page":"308","article-title":"\"Silymarin\", a promising pharmacological agent for treatment of diseases","volume":"14","author":"Karimi","year":"2011","journal-title":"Iran J Basic Med Sci"},{"issue":"9","key":"10.1016\/j.dsx.2025.103209_bib269","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0221683","article-title":"Silymarin in non-cirrhotics with non-alcoholic steatohepatitis: a randomized, double-blind, placebo controlled trial","volume":"14","author":"Navarro","year":"2019","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.dsx.2025.103209_bib270","doi-asserted-by":"crossref","DOI":"10.1016\/j.aohep.2023.101174","article-title":"Administration of silymarin in NAFLD\/NASH: a systematic review and meta-analysis","volume":"29","author":"Li","year":"2024","journal-title":"Ann Hepatol"},{"issue":"12","key":"10.1016\/j.dsx.2025.103209_bib271","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1038\/oby.2011.152","article-title":"Effects of combined exenatide and pioglitazone therapy on hepatic fat content in type 2 diabetes","volume":"19","author":"Sathyanarayana","year":"2011","journal-title":"Obesity"},{"issue":"9","key":"10.1016\/j.dsx.2025.103209_bib272","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1002\/hep4.1993","article-title":"Combination of tofogliflozin and pioglitazone for NAFLD: extension to the ToPiND randomized controlled trial","volume":"6","author":"Yoneda","year":"2022","journal-title":"Hepatol Commun"},{"issue":"3","key":"10.1016\/j.dsx.2025.103209_bib273","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/dom.13907","article-title":"Exenatide and dapagliflozin combination improves markers of liver steatosis and fibrosis in patients with type 2 diabetes","volume":"22","author":"Gastaldelli","year":"2020","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"10.1016\/j.dsx.2025.103209_bib274","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1111\/dom.14319","volume":"23","author":"Harreiter","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.dsx.2025.103209_bib275","doi-asserted-by":"crossref","DOI":"10.1097\/HEP.0000000000001254","article-title":"Comparison of pharmacological therapies in metabolic dysfunction-associated steatohepatitis for fibrosis regression and MASH resolution: systematic review and network meta-analysis","author":"Souza","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.dsx.2025.103209_bib276","doi-asserted-by":"crossref","DOI":"10.1111\/eci.70003","article-title":"Pharmacological treatment options for metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes mellitus: a systematic review","author":"Konings","year":"2025","journal-title":"Eur J Clin Invest"},{"issue":"5","key":"10.1016\/j.dsx.2025.103209_bib277","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1001\/jamainternmed.2016.9607","article-title":"Thiazolidinediones and advanced liver fibrosis in nonalcoholic steatohepatitis: a meta-analysis","volume":"177","author":"Musso","year":"2017","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.dsx.2025.103209_bib278","author":"Novo Nordisk"},{"issue":"4","key":"10.1016\/j.dsx.2025.103209_bib279","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1097\/HEP.0000000000000855","article-title":"Effects of empagliflozin on liver fat in patients with metabolic dysfunction-associated steatotic liver disease without diabetes mellitus: a randomized, double-blind, placebo-controlled trial","volume":"80","author":"Cheung","year":"2024","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.dsx.2025.103209_bib280","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12933-021-01237-2","article-title":"Effect of empagliflozin on ectopic fat stores and myocardial energetics in type 2 diabetes: the EMPACEF study","volume":"20","author":"Gaborit","year":"2021","journal-title":"Cardiovasc Diabetol"},{"issue":"4","key":"10.1016\/j.dsx.2025.103209_bib281","doi-asserted-by":"crossref","first-page":"668","DOI":"10.2337\/dc23-1646","article-title":"Empagliflozin reduces liver fat in individuals with and without diabetes","volume":"47","author":"Abdelgani","year":"2024","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.dsx.2025.103209_bib282","doi-asserted-by":"crossref","first-page":"298","DOI":"10.2337\/dc19-0641","article-title":"Empagliflozin effectively lowers liver fat content in well-controlled type 2 diabetes: a randomized, double-blind, phase 4, placebo-controlled trial","volume":"43","author":"Kahl","year":"2020","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1016\/j.dsx.2025.103209_bib283","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdiacomp.2023.108610","article-title":"Effect of dapagliflozin on liver and pancreatic fat in patients with type 2 diabetes and non-alcoholic fatty liver disease","volume":"37","author":"Shi","year":"2023","journal-title":"J Diabet Complicat"},{"issue":"12","key":"10.1016\/j.dsx.2025.103209_bib284","doi-asserted-by":"crossref","first-page":"3621","DOI":"10.1111\/dom.15257","article-title":"No evidence of compensatory changes in energy balance, despite reductions in body weight and liver fat, during dapagliflozin treatment in type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, cross-over trial (ENERGIZE)","volume":"25","author":"Rajeev","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.dsx.2025.103209_bib285","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2022.109781","article-title":"Metabolic changes induced by dapagliflozin, an SGLT2 inhibitor, in Japanese patients with type 2 diabetes treated by oral anti-diabetic agents: a randomized, clinical trial","volume":"186","author":"Horibe","year":"2022","journal-title":"Diabetes Res Clin Pract"},{"issue":"4","key":"10.1016\/j.dsx.2025.103209_bib286","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinre.2021.101816","article-title":"Efficacy of statins in treatment and development of non-alcoholic fatty liver disease and steatohepatitis: a systematic review and meta-analysis","volume":"46","author":"Fatima","year":"2022","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"2","key":"10.1016\/j.dsx.2025.103209_bib287","doi-asserted-by":"crossref","first-page":"296","DOI":"10.3904\/kjim.2017.194","article-title":"Ezetimibe decreased nonalcoholic fatty liver disease activity score but not hepatic steatosis","volume":"34","author":"Lee","year":"2019","journal-title":"Korean J Intern Med"},{"issue":"2","key":"10.1016\/j.dsx.2025.103209_bib288","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbamcr.2023.119649","article-title":"Blockade of angiotensin II modulates insulin-like growth factor 1-mediated skeletal muscle homeostasis in experimental steatohepatitis","volume":"1871","author":"Tanaka","year":"2024","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"issue":"1","key":"10.1016\/j.dsx.2025.103209_bib289","article-title":"Effects of losartan in patients with NAFLD: a meta-analysis of randomized controlled trial","volume":"18","author":"Meng","year":"2023","journal-title":"Open Life Sci"},{"issue":"12","key":"10.1016\/j.dsx.2025.103209_bib290","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1111\/dom.12989","article-title":"Effects of combined low-dose spironolactone plus vitamin E vs vitamin E monotherapy on insulin resistance, non-invasive indices of steatosis and fibrosis, and adipokine levels in non-alcoholic fatty liver disease: a randomized controlled trial","volume":"19","author":"Polyzos","year":"2017","journal-title":"Diabetes Obes Metab"},{"issue":"9","key":"10.1016\/j.dsx.2025.103209_bib291","doi-asserted-by":"crossref","DOI":"10.3390\/nu12092769","article-title":"Effects of omega-3 polyunsaturated fatty acid supplementation on non-alcoholic fatty liver: a systematic review and meta-analysis","volume":"12","author":"Lee","year":"2020","journal-title":"Nutrients"},{"key":"10.1016\/j.dsx.2025.103209_bib292","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2022.880749","article-title":"Endoscopic bariatric and metabolic therapies and their effects on metabolic syndrome and non-alcoholic fatty liver disease - a systematic review and meta-analysis","volume":"9","author":"Lee","year":"2022","journal-title":"Front Med"},{"issue":"6","key":"10.1016\/j.dsx.2025.103209_bib293","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1007\/s12664-021-01202-7","article-title":"Endoscopic sleeve gastroplasty - minimally invasive treatment for non-alcoholic fatty liver disease and obesity","volume":"40","author":"Jagtap","year":"2021","journal-title":"Indian J Gastroenterol"},{"issue":"8","key":"10.1016\/j.dsx.2025.103209_bib294","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1007\/s11695-020-04644-8","article-title":"Intragastric balloon versus endoscopic sleeve gastroplasty for the treatment of obesity: a systematic review and meta-analysis","volume":"30","author":"Singh","year":"2020","journal-title":"Obes Surg"},{"issue":"17","key":"10.1016\/j.dsx.2025.103209_bib295","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10173783","article-title":"Effects of roux-en-Y gastric bypass and sleeve gastrectomy on non-alcoholic fatty liver disease: a 12-month follow-up study with paired liver biopsies","volume":"10","author":"Pedersen","year":"2021","journal-title":"J Clin Med"},{"issue":"Suppl","key":"10.1016\/j.dsx.2025.103209_bib296","doi-asserted-by":"crossref","first-page":"S276","DOI":"10.3350\/cmh.2022.0373","article-title":"Bariatric surgery for non-alcoholic fatty liver disease: indications and post-operative management","volume":"29","author":"Geerts","year":"2023","journal-title":"Clin Mol Hepatol"},{"issue":"3","key":"10.1016\/j.dsx.2025.103209_bib297","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.soard.2018.12.002","article-title":"Bariatric surgery improves nonalcoholic fatty liver disease: a contemporary systematic review and meta-analysis","volume":"15","author":"Fakhry","year":"2019","journal-title":"Surg Obes Relat Dis"}],"container-title":["Diabetes & Metabolic Syndrome: Clinical Research & Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871402125000268?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871402125000268?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T23:43:49Z","timestamp":1762559029000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1871402125000268"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":297,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S1871402125000268"],"URL":"https:\/\/doi.org\/10.1016\/j.dsx.2025.103209","relation":{},"ISSN":["1871-4021"],"issn-type":[{"value":"1871-4021","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Consensus guidelines for the diagnosis and management of metabolic dysfunction-associated steatotic liver disease in adult Asian Indians with type 2 diabetes","name":"articletitle","label":"Article Title"},{"value":"Diabetes & Metabolic Syndrome: Clinical Research & Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dsx.2025.103209","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Research Trust of DiabetesIndia (DiabetesIndia) and National Diabetes Obesity and Cholesterol Foundation (N-DOC). Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103209"}}